KALV
KalVista Pharmaceuticals, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Jun 11. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q2 2026: 0 added (0 new), 15 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.379 → −$0.287 over 90 days. 4 up, 2 down in 30 days.
- Short sellersCOVERING
Short interest −43.2% to 6.84M shares. 2.0 days to cover.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| Capital World Investors | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| GOLDMAN SACHS GROUP INC | EXIT | $0.00 |
| UBS Group AG | EXIT | $0.00 |
| Point72 Asset Management, L.P. | EXIT | $0.00 |
| MILLENNIUM MANAGEMENT LLC | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action May 2026| Date | Firm | Rating |
|---|---|---|
| May 1, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Apr 30, 2026 | Needham DOWNGRADE | Hold |
| Mar 26, 2026 | Stifel MAINTAIN | Buy |
| Mar 26, 2026 | Citizens MAINTAIN | Market Outperform |
| Mar 25, 2026 | Needham MAINTAIN | Buy |
| Jan 9, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Piekos Brian Chief Financial Officer Jun 11, 2026 | TO ISSUER | 21,661 sh |
Palleiko Benjamin L CHIEF EXECUTIVE OFFICER Jun 11, 2026 | TO ISSUER | 479,989 sh |
Yea Christopher CHIEF DEVELOPMENT OFFICER Jun 11, 2026 | TO ISSUER | 229,918 sh |
Yea Christopher CHIEF DEVELOPMENT OFFICER Jun 11, 2026 | TO ISSUER | 25,000 sh |
Yea Christopher CHIEF DEVELOPMENT OFFICER Jun 11, 2026 | TO ISSUER | 53,500 sh |
Palleiko Benjamin L CHIEF EXECUTIVE OFFICER Jun 11, 2026 | TO ISSUER | 125,001 sh |
Piekos Brian Chief Financial Officer Jun 11, 2026 | TO ISSUER | 100,000 sh |
Piekos Brian Chief Financial Officer Jun 11, 2026 | TO ISSUER | 55,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.29 | -$0.43–-$0.02 | -10.3% | $49.2M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$0.88 | -$1.70–$0.59 | -9.2% | $213.5M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· May 29, 2026SecBot reports
12 filings · 1 bullish · 6 bearish · 5 neutral- BEARISH 15-12GJun 22, 2026
KalVista Pharmaceuticals filed a Form 15-12G to terminate its SEC registration under Section…
With only one holder of record and SEC reporting suspended, the stock will likely be delisted from Nasdaq and move to the OTC markets with minimal liquidity. Existing shareholders should expect no…
- NEUTRAL EFFECTJun 17, 2026
KalVista Pharmaceuticals' shelf registration statement (Form S-3, File No. 333-280759) was…
Monitor for any takedown announcements under the shelf, which would trigger actual dilution. The effectiveness itself is routine; the real impact depends on whether and when the company sells shares.
- NEUTRAL 8-KJun 11, 2026
Chiesi Farmaceutici S.p.A. completed its acquisition of KalVista Pharmaceuticals for $27.00 per…
The acquisition is complete and KALV common stock is no longer trading. Remaining public shareholders who did not tender will receive $27.00 per share through the merger. Convertible note holders…
- NEUTRAL INST-CLUSTERJun 11, 2026
An institutional cluster for KalVista Pharmaceuticals shows 4 passive buyers (Wells Fargo, Schwab…
The cluster is dominated by passive rebalancing with no active hedge fund or family office involvement. This provides no actionable directional signal. Monitor for filings from active managers or…
All KALV filing & press-release reports (12)
- 15-12G reportJun 22, 2026
- EFFECT reportJun 17, 2026
- 8-K reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 19, 2026
- CLUSTER reportMay 19, 2026
- 8-K reportApr 29, 2026
- CLUSTER reportApr 17, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER, CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026